{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T04:45:29Z","timestamp":1744173929461},"reference-count":10,"publisher":"Cambridge University Press (CUP)","issue":"1","license":[{"start":{"date-parts":[[2006,2,3]],"date-time":"2006-02-03T00:00:00Z","timestamp":1138924800000},"content-version":"unspecified","delay-in-days":33,"URL":"https:\/\/www.cambridge.org\/core\/terms"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cardiol Young"],"published-print":{"date-parts":[[2006,1]]},"abstract":"<jats:p>Oral sildenafil has been demonstrated to be an effective treatment for pulmonary hypertension, and is increasingly used in children. We report an infant with pulmonary hypertension, stable on regular treatment with oral sildenafil, who presented in acute respiratory failure after aspiration, requiring ventilation and intensive care. The course of the stay in intensive care was difficult, with recurrent pulmonary hypertensive crises despite use of oral sildenafil, use of 100% oxygen, high frequency oscillatory ventilation, and inhaled nitric oxide. In view of his instability, and the presumed inability to absorb the sildenafil orally due to gastrointestinal malabsorption, sildenafil was administered as a continuous intravenous infusion. With this therapy, it proved possible to wean from oxygen, nitric oxide, and ventilatory support. Intravenous sildenafil, therefore, might be an effective alternative for children with pulmonary hypertension during episodes of acute deterioration and malabsorption, preventing life-threatening pulmonary hypertensive crises. Its pharmacokinetics, efficacy, and safety, nonetheless, need to be validated in randomized controlled trials.<\/jats:p>","DOI":"10.1017\/s1047951105002155","type":"journal-article","created":{"date-parts":[[2006,2,3]],"date-time":"2006-02-03T11:18:05Z","timestamp":1138965485000},"page":"84-86","source":"Crossref","is-referenced-by-count":12,"title":["Intravenous sildenafil as an effective treatment of pulmonary hypertensive crises during acute intestinal malabsorption"],"prefix":"10.1017","volume":"16","author":[{"given":"Astrid E.","family":"Lammers","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheila G.","family":"Haworth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine M.","family":"Pierce","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"56","published-online":{"date-parts":[[2006,2,3]]},"reference":[{"key":"S1047951105002155_ref010","doi-asserted-by":"crossref","unstructured":"Stocker C , Penny DJ , Brizard CP , Cochrane AD , Soto R , Sherkerdemian LS . Intravenous Sildenafil and inhaled nitric oxide: a randomized trial in infants after cardiac surgery. Intensive Care Med 2003; 29: 1996\u20132003.","DOI":"10.1007\/s00134-003-2016-4"},{"key":"S1047951105002155_ref001","doi-asserted-by":"crossref","unstructured":"Ghofrani HA , Wiedemann R , Rose F , et al. Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomized controlled trial. Lancet 2002; 360: 895\u2013900.","DOI":"10.1016\/S0140-6736(02)11024-5"},{"key":"S1047951105002155_ref004","doi-asserted-by":"crossref","unstructured":"Stiebellehner L , Petkov V , Vonbank K et al. Long-term treatment with oral Sildenafil in addition to continuous iv Epoprostenol in patients with pulmonary arterial hypertension. Chest 2003; 123: 1293\u20131295.","DOI":"10.1378\/chest.123.4.1293"},{"key":"S1047951105002155_ref008","doi-asserted-by":"crossref","unstructured":"Sherkerdemian LS , Ravn HB , Penny DJ . Intravenous Sildenafil lowers pulmonary vascular resistance in a model of neonatal pulmonary hypertension. Am J Resp Crit Care Med 2002; 165: 1098\u20131102.","DOI":"10.1164\/ajrccm.165.8.2107097"},{"key":"S1047951105002155_ref009","doi-asserted-by":"crossref","unstructured":"Schulze-Neick I , Hartenstein P , Li J et al. Intravenous Sildenafil is a potent pulmonary vasodilator in children with congenital heart disease. Circulation 2003; 108 (Suppl III): II-167\u2013II-173.","DOI":"10.1161\/01.cir.0000087384.76615.60"},{"key":"S1047951105002155_ref003","doi-asserted-by":"crossref","unstructured":"Sastry BK , Narasimhan C , Reddy NK , Raju BS . Clinical efficacy of Sildenafil in primary pulmonary hypertension: a randomized, placebo controlled, double blind, cross over study. J Am Coll Cardiol 2004; 43: 1149.","DOI":"10.1016\/j.jacc.2003.10.056"},{"key":"S1047951105002155_ref005","doi-asserted-by":"crossref","unstructured":"Leuchte HH , Schwaiblmair M , Baumgartner RA , Neurohr CF , Kolbe T , Behr J . Hemodynamic response to Sildenafil, nitric oxide, and Iloprost in primary pulmonary hypertension. Chest 2004; 125: 580\u2013586.","DOI":"10.1378\/chest.125.2.580"},{"key":"S1047951105002155_ref002","doi-asserted-by":"crossref","unstructured":"Prasad S , Wilkinson J , Gatzoulis MA . Sildenafil in primary pulmonary hypertension. N Eng J Med 2000; 343: 1342.","DOI":"10.1056\/NEJM200011023431814"},{"key":"S1047951105002155_ref007","doi-asserted-by":"crossref","unstructured":"Abrams D , Schulze-Neick I , Magee AG . Sildenafil as a selective pulmonary vasodilator in childhood primary pulmonary hypertension. Heart 2000; 84: E4.","DOI":"10.1136\/heart.84.2.e4"},{"key":"S1047951105002155_ref006","doi-asserted-by":"crossref","unstructured":"Rabe KF , Tenor H , Dent G , Schudt C , Nakashima M , Magnussen H . Identification of PDE isozymes in human pulmonary artery and effect of selective PDE inhibitors. Am J Physiol 1994; 266: L536\u2013L543.","DOI":"10.1152\/ajplung.1994.266.5.L536"}],"container-title":["Cardiology in the Young"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S1047951105002155","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,16]],"date-time":"2019-04-16T18:18:43Z","timestamp":1555438723000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S1047951105002155\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,1]]},"references-count":10,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2006,1]]}},"alternative-id":["S1047951105002155"],"URL":"https:\/\/doi.org\/10.1017\/s1047951105002155","relation":{},"ISSN":["1047-9511","1467-1107"],"issn-type":[{"value":"1047-9511","type":"print"},{"value":"1467-1107","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,1]]}}}